Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > So the CEO said LABS waiting on drug monograph from FDA
View:
Post by subaru1i on Jul 25, 2023 9:49pm

So the CEO said LABS waiting on drug monograph from FDA

What is a drug monograph and how much is that drug monograph worth in price per share.   Just the first drug for starters.   I honestly don't know if some that post here are 'basher like' or just not well read on what they invested in.   Hopefully it's not being well read because if that's the case, you shouldn't be playing with your money in the stock market.   We're waiting....to be continued. 

A Product (or Drug) Monograph is a factual, scientific document on a drug product that, devoid of promotional material, describes the properties, claims, indications, and conditions of use of the drug and contains any other information that may be required for optimal, safe and effective use of the drug. 
Comment by subaru1i on Jul 26, 2023 9:38am
ps:  IIROC does not reply to neither to confirm or deny when a report is submitted regarding illegal trading practices.   Some times gathering evidence can span over several years. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities